yeiB Antibody

How are neutralizing antibodies identified from convalescent patients?

Identification of neutralizing antibodies from convalescent patients involves a systematic process starting with isolation of peripheral blood mononuclear cells (PBMCs) from blood samples. This typically follows these methodological steps:

• Isolation of B cells specific to the pathogen of interest using fluorescently-labeled antigens

• Single-cell RNA sequencing to obtain paired heavy- and light-chain sequences

• Expression of recombinant antibodies in mammalian cell systems

• Screening for binding and neutralizing activity

• Detailed functional characterization of promising candidates

For example, researchers investigating EBOV-specific antibodies sorted approximately 100,000 EBOV GP-reactive memory B cells from a convalescent donor and performed large-scale single-cell antibody gene sequencing. This enabled analysis of the ebolavirus-specific antibody repertoire both genetically and functionally . Researchers identified 73 public clonotypes, with 20% encoding antibodies that demonstrated neutralization activity and capacity to protect mice in vivo .

What methods are used to measure antibody binding affinity?

Several robust methodologies are employed to quantify antibody-antigen binding affinity:

For accurate affinity determination, it's essential to use purified proteins under controlled conditions to eliminate artifacts from avidity effects or non-specific binding. The choice of method depends on the specific research question, with SPR and BLI providing the most detailed kinetic information.

How do surrogate virus neutralization tests (sVNTs) compare to conventional neutralization assays?

Surrogate virus neutralization tests offer several methodological advantages over conventional virus neutralization tests:

Safety advantages:

• sVNTs don't require handling live viruses, eliminating the need for BSL-3/BSL-4 containment

• Can be performed in standard laboratory settings with minimal biohazard risk

• Particularly valuable for highly pathogenic viruses like SARS-CoV-2 or EBOV

Technical considerations:

• Higher throughput capacity suitable for large-scale screening

• More easily standardized across different laboratories

• Typically less labor-intensive and time-consuming

How can germline-targeting immunogens be designed to elicit broadly neutralizing antibodies?

Designing germline-targeting immunogens to elicit broadly neutralizing antibodies (bnAbs) against viruses with high antigenic diversity requires sophisticated engineering approaches:

• Identification of bnAb Precursors:

  • Revert mature bnAbs to their germline configurations

  • Characterize binding properties of germline antibodies

  • Map the minimal mutations needed for neutralization activity

• Structure-Based Immunogen Design:

  • Computational modeling to optimize binding to germline antibodies

  • Directed evolution via yeast surface display to improve binding

  • Creation of epitope scaffolds displaying critical binding determinants

• Affinity Gradient Creation:
  For example, in HIV research, scientists developed the 10E8-GT series of immunogens that progressively bound to more germline antibody precursors with increasing affinity:

  Immunogen Version	Percentage of Precursors Bound	Affinity (Kd)
  10E8-GT9.2	15%	22 μM
  10E8-GT10.1	22%	Improved
  10E8-GT10.2	60%	Further improved

• Multivalent Display Strategies:

  • Present epitope scaffolds on self-assembling nanoparticles

  • Optimize spacing for effective B cell receptor crosslinking

  • Add N-linked glycosylation to reduce off-target responses

This approach successfully induced B cells with long HCDR3s containing specific binding motifs (YxFW) necessary for development into 10E8-class bnAbs in both mice and rhesus macaques .

What strategies can overcome challenges in generating antibodies against membrane proteins?

Generating antibodies against membrane proteins like G protein-coupled receptors (GPCRs) presents significant technical challenges due to their complex structure with seven transmembrane domains and limited extracellular regions. Several methodological advances have improved success rates:

• Expression Enhancement Technologies:

  • Conjugation of P9 peptide (from Pseudomonas phi6) to the N-terminus improves expression in E. coli

  • Codon optimization for the expression system of choice

  • Use of specialized eukaryotic expression systems for complex proteins

• Stabilization Strategies:

  • Amphiphilic poly-γ-glutamate (APG) shields hydrophobic transmembrane domains

  • Introduction of stabilizing mutations to lock proteins in specific conformations

  • Use of lipid nanodiscs to maintain native membrane environment

• Advanced Display Technologies:

  • Phage display with synthetic antibody libraries

  • Yeast display systems for more complex proteins

  • Mammalian display to ensure proper folding and post-translational modifications

• Conformational Epitope Preservation:

  • Present extracellular loops in native-like conformations

  • Use of conformation-specific probes during selection

These approaches enable preparation of membrane proteins in their active forms, dramatically improving the likelihood of generating functionally relevant antibodies that recognize native conformations .

How can antibodies be redesigned to enhance cross-reactivity while maintaining specificity?

Antibody redesign for enhanced cross-reactivity requires sophisticated protein engineering approaches to identify mutations that broaden recognition without compromising specificity:

• Empirical Computational Chemistry Approach:

  • Capture key physicochemical features common to antigen-antibody interfaces

  • Predict protein-protein interactions and beneficial mutations

  • Focus on paratope regions that can accommodate changes while maintaining core interactions

• Paratope Mapping Without Crystal Structures:

  • Identify antibody amino acids suitable for mutation using alanine scanning mutagenesis

  • Employ computational models to predict effects of mutations

  • Create libraries focused on key complementarity-determining regions (CDRs)

• Combinatorial Testing Strategies:

  • Test individual mutations first to assess their effects

  • Combine beneficial mutations to achieve additive or synergistic effects

  • Validate using binding and functional assays against multiple antigens

A notable example demonstrated this approach for dengue virus, where researchers engineered an antibody with a 450-fold improvement in affinity to serotype 4 while preserving or modestly increasing affinity to serotypes 1-3. This resulted in strong neutralizing activity against all four serotypes both in vitro and in a mouse model .

How can phage display technology be optimized for isolating antibodies against complex viral proteins?

Optimizing phage display technology for isolating antibodies against complex viral proteins requires methodological refinements at multiple stages:

• Library Design Considerations:

  • Use diverse synthetic or natural antibody libraries (>10^9 members)

  • Consider specialized libraries with tailored CDR lengths for targeting recessed epitopes

  • Incorporate natural or synthetic diversity in key paratope regions

• Biopanning Optimization:

  • Implement negative selection against related proteins to remove cross-reactive binders

  • Use alternating presentation formats (recombinant protein, virus-like particles, cells)

  • Consider competitive elution with known ligands to select for specific epitopes

  • Gradually increase stringency of washing steps in successive rounds

• Screening Methodology:

  • Develop high-throughput functional screening assays

  • Include both binding and neutralization assays early in the process

  • Test cross-reactivity against variant forms of the target protein

In a SARS-CoV-2 study, researchers successfully isolated four spike protein-specific single-chain variable fragments (scFvs), converted them to monoclonal antibodies, and identified a pair (K104.1 and K104.2) with high binding affinities (1.3 nM and 1.9 nM). These antibodies bound to different sites on the S2 subunit, enabling development of a sandwich immunoassay that detected multiple variants including Alpha, Beta, Gamma, Delta, Kappa, and Omicron .

What approaches determine if antibody-dependent enhancement (ADE) will occur with therapeutic antibodies?

Assessing the risk of antibody-dependent enhancement (ADE) is critical for therapeutic antibody development, particularly for viruses with known ADE potential. Multiple complementary approaches provide a comprehensive risk assessment:

• Cellular Assay Systems:

  • Test antibody-mediated viral infection in FcR-bearing cells (monocytes, macrophages)

  • Compare infection rates and viral replication ± antibody across concentration ranges

  • Use flow cytometry and quantitative PCR to measure infection and viral replication

• Pseudovirus Systems:

  • Engineer pseudotyped viruses expressing the viral envelope protein

  • Test entry into cells expressing different Fc receptors

  • Provides safer alternative to working with infectious viruses

• Fc Engineering Approaches:

  • Test variants with modified Fc regions that reduce or eliminate FcR binding

  • Compare protective efficacy of modified vs. unmodified antibodies

  • Use point mutations (e.g., LALA mutations) or isotype switching

• In Vivo Assessment:

  • Evaluate in relevant animal models across dose ranges

  • Monitor for enhanced disease severity or increased viral loads

  • Assess inflammatory markers that might indicate ADE

For example, with the CT-P59 antibody against SARS-CoV-2, researchers conducted in vitro assays showing no antibody-mediated increase in viral infections in FcR-bearing cells. This finding aligned with the absence of symptom worsening in treated animals across three different models (ferret, hamster, and rhesus monkey) .

What factors affect neutralizing antibody production following vaccination?

The production of neutralizing antibodies following vaccination is influenced by numerous interacting factors that researchers must consider when designing and evaluating vaccines:

Host-Related Factors:

Vaccine-Related Factors:

• Antigen design and presentation format

• Adjuvant type and formulation

• Delivery platform (mRNA, viral vector, protein)

• Dosing schedule and interval between doses

• Antigen dose per administration

Measurement Considerations:

• Timing of assessment relative to vaccination

• Assay methodology (binding vs. neutralization)

• Virus variant used in neutralization assays

Interestingly, adverse reactions following vaccination (particularly systemic ones) may correlate with stronger immune responses, although this relationship requires further investigation . Understanding these factors is essential for optimizing vaccination strategies, particularly for vulnerable populations.

How can epitope scaffolding be used to design immunogens that elicit antibodies with predefined genetic properties?

Epitope scaffolding represents an advanced approach to rational immunogen design for eliciting antibodies with specific genetic and structural features:

• Structural Analysis and Epitope Definition:

  • Determine atomic structure of target epitope bound by desired antibody

  • Identify critical contact residues essential for recognition

  • Analyze structural constraints necessary for proper epitope presentation

• Computational Scaffold Selection:

  • Screen protein structure databases for scaffolds capable of supporting the epitope

  • Use computational modeling to graft epitope onto candidate scaffolds

  • Optimize scaffold-epitope interface to minimize strain

• Germline-Targeting Modifications:

  • Engineer epitope to enhance binding to germline B cell receptors

  • Use directed evolution (yeast display) for iterative optimization:

    Design Stage	Method	Outcome
    Initial design	Structure-based modeling	Baseline binding
    Optimization	Combinatorial NNK patch scanning	Identification of optimal amino acid combinations
    Affinity maturation	Yeast display selection	Progressively improved binding to germline antibodies

• Multivalent Presentation Strategies:

  • Display epitope scaffolds on self-assembling nanoparticles

  • Optimize spacing and orientation for B cell receptor crosslinking

  • Add glycans to shield non-epitope regions

In HIV research, this approach successfully induced B cells with long HCDR3s containing a specific binding motif (YxFW) crucial for development into 10E8-class broadly neutralizing antibodies. Among epitope-specific B cells, 47-87% contained the critical motif, compared to just 1.4% in the general B cell population .

What challenges exist in developing antibodies that target specific isoforms of proteins?

Developing antibodies that selectively target specific isoforms of biologically active proteins presents several methodological challenges:

• Epitope Identification Challenges:

  • Identifying unique epitopes not shared between isoforms

  • Ensuring epitope accessibility in the native conformation

  • Addressing potential masking in higher-order structures

• Isoform-Specific Screening Requirements:

  • Development of assays that discriminate between closely related isoforms

  • Implementation of counter-screening against non-target isoforms

  • Validation in complex biological matrices containing all isoforms

• Structural Considerations:

  • Different isoforms may share primary sequence but adopt distinct tertiary structures

  • Post-translational modifications may differentiate otherwise identical sequences

  • Oligomerization states may differ between isoforms

• Functional Validation Needs:

  • Demonstrating selective modulation of isoform-specific biological activities

  • Confirming lack of interference with beneficial isoform functions

  • Testing in relevant disease models

In an adiponectin study, researchers successfully generated monoclonal antibodies with different isoform specificities, as shown below:

This demonstrates the potential of isoform-specific antibodies to selectively modulate pathological activities while preserving beneficial functions of other isoforms .

How can crystal structures of antibody-antigen complexes guide therapeutic antibody development?

Crystal structures of antibody-antigen complexes provide crucial information that guides therapeutic antibody development through multiple mechanistic insights:

• Epitope Characterization:

  • Precise mapping of contact residues at atomic resolution

  • Identification of critical binding determinants

  • Assessment of epitope conservation across variants

  For example, crystallography of CT-P59 Fab/RBD complex revealed that this antibody blocks interaction regions of SARS-CoV-2 RBD for ACE2 receptor with an orientation notably different from previously reported RBD-targeting antibodies .

• Binding Mode Analysis:

  • Understanding of antibody approach angle and binding orientation

  • Identification of hydrogen bonds, salt bridges, and hydrophobic interactions

  • Determination of conformational changes upon binding

• Antibody Engineering Applications:

  • Structure-guided mutation of CDRs to enhance affinity

  • Modification of framework regions to improve stability

  • Introduction of cross-reactivity while maintaining specificity

  In MERS-CoV research, crystallography identified three critical epitopes (D509, R511, and E513) in the RBD region of the spike protein that were essential for neutralization .

• Escape Variant Prediction:

  • Identification of residues under structural constraint

  • Prediction of mutations that might confer resistance

  • Design of antibody combinations targeting non-overlapping epitopes

• Germline Repertoire Understanding:

  • Insights into how germline-encoded features contribute to recognition

  • Identification of somatic hypermutations critical for function

  • Classification of antibodies into structural classes based on binding mode

  For SARS-CoV-2, structural studies revealed that many neutralizing antibodies belong to the IGHV3 germline, while CT-P59 (based on IGHV2-70) binds with a distinct orientation, contributing to its unique properties .

How might new technologies transform detection of antibody responses to emerging pathogens?

Emerging technologies are poised to revolutionize how we detect and characterize antibody responses to novel pathogens, addressing current limitations in sensitivity, specificity, and throughput:

• Next-Generation Sequencing Applications:

  • Paired heavy and light chain sequencing from single B cells

  • Comprehensive analysis of entire B cell repertoires

  • Identification of public clonotypes shared across individuals

  Research on EBOV demonstrated the power of deep paired sequencing, identifying 73 public clonotypes from memory B cells, with 20% showing neutralization activity .

• Synthetic Biology Approaches:

  • Yeast display libraries of viral protein variants

  • High-throughput mapping of antibody epitopes

  • Identification of escape mutations under antibody pressure

• Advanced Structural Biology Methods:

  • Cryo-electron microscopy for rapid structure determination

  • Hydrogen-deuterium exchange mass spectrometry for epitope mapping

  • Computational prediction of antibody-antigen interactions

• Novel Assay Platforms:

  • Multiplex systems detecting responses to multiple antigens simultaneously

  • Surrogate virus neutralization tests for safer, more standardized assessment

  • Microfluidic systems for high-throughput single-cell analysis

  Commercial surrogate virus neutralization tests have shown good correlation with conventional neutralization assays while offering increased safety and throughput .

• Artificial Intelligence Integration:

  • Machine learning algorithms for predicting neutralization from binding data

  • Deep learning models identifying correlates of protection

  • AI-assisted design of antibody therapeutics based on early response data